MolecularEd Webinar: New Approaches to Hepatitis C Testing, Moderator Christopher Hall MD

Published On: February 20, 2022By Categories: MolecularEd, Research & DevelopmentTags: ,



Treatment of Hepatitis C (HCV) has been revolutionized by the introduction of directly acting antiviral medications, but identification of affected individuals who are candidates for such treatment remains a pressing public health challenge. While both self-collected specimen and point-of-care (POC) testing for HCV antibodies have been available for years now, use of these tests still requires patients to complete a second round of testing – typically in person – to determine whether detectable HCV virus is present, signaling infection necessitating treatment and also reflecting ongoing transmissibility of the virus. Molecular Testing Labs has introduced a viral load test (for RNA by PCR) utilizing a dried blood spot (DBS) collection device that patients can complete on their own or have collected as part of community outreach efforts offering fingerstick POC antibody testing.

This webinar highlights the need for such innovative testing aimed at decreasing barriers to hepatitis C testing and diagnosis. Watch to learn more about self-collect HCV testing on DBS, as well as how this test can be combined with fingerstick POC antibody tests to minimize patient wait times, limit loss to follow-up, and improve linkage to effective HCV care.

MODERATOR: Christopher Hall, MD, MS, AAHIVS. Clinical Medical Director, Molecular Testing Labs.


  • Andrew Seaman, MD. Central City Concern (Portland, OR) and Assistant Professor of Medicine, Oregon Health & Science University.
  • Caitlin Conyngham. Senior Manager of Clinical Adoption, OraSure Technologies.
  • Charles Sailey, MD, MS. Laboratory Director, Molecular Testing Labs.
  • Brad Thorson. Director of Business Development, Molecular Testing Labs.

About the Author: Staff

Molecular Testing Labs is headquartered in Vancouver, Washington. Molecular’s leaders are visionary in their approach to precision laboratory diagnostics and are committed to revolutionizing accessibility to testing via proprietary technology systems, advanced logistics, and cutting-edge research and development. They provide laboratory solutions through collaborative partnerships with payors, private healthcare institutions, universities, commercial partners, and public health organizations. Molecular Testing Labs is a CLIA- and CAP-accredited, state-of-the-art reference laboratory that is passionate about bridging the gap and building bonds between the large communities that have access to diagnostics and the smaller underserved communities that deserve that same access. Molecular Testing Labs is pioneering distribution and specimen collection methods that open access to medical testing where geographic, financial, and stigma barriers create gaps in the delivery of healthcare.